investigated. All the drugs tested inhibited the binding of fibrinogen to leukaemia cells. This effect was particularly marked for drugs that act as inhibitors of protein synthesis. Since these anti-neoplastic drugs do not have anti-coagulant actions, these results provide evidence for the potential of targeting tumour fibrinogen as a new form of cancer chemotherapy.
Introduction
Tumour metastasis involves a number of complex processes and mechanisms. Knowledge of these processes can guide the development of appropriate treatments to improve survival rates in cancer patients. Tumour metastasis has been reported to be linked to the haemostatic coagulant system, especially to fibrin and/or fibrinogen in sera and within the tumour matrix. 1 The deposition of fibrin and/or fibrinogen in the tumour stroma facilitates tumour growth and metastasis by at least three processes: (i) It may form a scaffold to which tumour cells can attach; (ii) It may form a cocoon to shield tumour cells from attack by activated lymphocytes; (iii) It may aid angiogenesis in tumour tissues. 2, 3 We have shown in clinical studies that cancer patients have raised plasma fibrinogen levels, 4 and the association between metastasis and fibrinogen has been demonstrated experimentally. 5 Fibrin and/or fibrinogen are therefore thought to promote tumour growth, and altering fibrinogen binding may be a possible mechanism of action for anti-neoplastic drugs.
This study investigated the effects of various anti-neoplastic drugs on the binding of fibrinogen to leukaemia cell lines, to test this hypothesis.
Materials and methods
Leukaemia cell lines P388 and HL-60 were cultured and passaged in our own laboratory (they were originally purchased from National Cancer Institute, National 
ANALYSIS OF FIBRINOGEN BINDING
Leukaemia cells in the exponential growth phase were collected from culture flasks, washed in serum-free RPMI 1640 medium (Gibco Co., NY, USA) and centrifuged at 900 g for 10 min. They were then suspended in serum-free RPMI 1640 at a concentration of 2 × 10 5 cells/ml. A 0.5 ml sample of the cell suspension was transferred to an Eppendorf tube; 0.1 ml of the drug being tested was added to the tube and incubated for 10 min. 125 I-Fibrinogen was added to the tumour cells at a concentration of 3.7 × 10 5 Bq/tube and incubated for 5 min, and the samples were then centrifuged at 12 000 g for 2 min. The radioactivity of the cell pellets produced was counted using a gamma radiometer (Beckman 5500, Beckman Coulter Inc., Fullerton, CA, USA). The radioactivity of control samples, to which no drug was For each drug, two concentrations were tested: the first was approximately within the clinical range for that drug and the second was a quarter of this concentration.
DATA ANALYSIS
Results were expressed as the mean ± SD of three samples. The Student's t-test was used to assess the effects of the various drugs on fibrinogen binding. A P-value < 0.01 was considered to be statistically significant.
Results
The anti-neoplastic drugs tested all decreased the binding of 125 I-Fibrinogen to the leukaemia cell lines P388 and HL-60; most of these differences were statistically significant (Tables 1 and 2 ). Inhibition of fibrinogen binding was concentration dependent. Drugs that act as inhibitors of protein synthesis, such as razoxane, probimane, 6 cyclophosphamide, harringtonine and homoharringtonine, appeared to have a greater inhibitory effect than drugs from other categories.
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Discussion
Controlling the amount of fibrinogen and/or fibrin in tumour stroma for the treatment of cancer metastasis has been attempted using anti-coagulants for over 30 years, 1 and some anti-coagulants have been reported to inhibit tumour growth and metastasis. 7, 8 However, the benefits of anti-coagulants are largely undermined by their effects on coagulation and bleeding. Haemorrhage caused by anticoagulants may be countered by vitamin K treatment, but patients receiving anticoagulants require constant monitoring. 9 It has been demonstrated that patients whose tumours are not surgically removed show a steady increase in blood fibrinogen, 4 and some tumour cell lines grown in vitro have shown evidence of expressing and assembling fibrinogen. 10 For over 10 years we have been developing a novel hypothesis that some anti-neoplastic drugs may affect metastasis by controlling the amount of fibrinogen and/or fibrin in the tumour stroma. This would be achieved via a pathway other than the plasma coagulation cascades. In this study, tumour cells had reduced fibrinogen binding ability when incubated with anti-neoplastic drugs. The anti-neoplastic drugs used in this study do not have anti-coagulant effects, yet inhibited the binding of fibrinogen to tumour cells in a statistically significant manner. These results provide evidence for the potential of targeting tumour fibrinogen as a new form of cancer chemotherapy.
